Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9786339 | 0.73 | MEN1 (0.33) | MEN1LMNAKMT2A | |
| SCHEMBL28411682 | 0.71 | — | — | |
| SCHEMBL1345866 | 0.71 | — | — | |
| SCHEMBL9798387 | 0.69 | — | — | |
| SCHEMBL734550 | 0.67 | TSHR (0.37) | MEN1LMNAKMT2A | |
| SCHEMBL2300964 | 0.67 | — | — | |
| SCHEMBL11292935 | 0.67 | TSHR (0.30) | — | |
| SCHEMBL1131779 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL28874171 | 0.65 | TSHR (0.35) | MEN1LMNAKMT2A | |
| SCHEMBL12814156 | 0.65 | MEN1 (0.33) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107754769-B | High-load metal chelating affinity chromatography medium | 苏州博进生物技术有限公司 | 2020-07-14 | — | — | CN | claimed |
| CN-107899552-B | Metal chelating affinity chromatography medium using magnetic polymer microsphere as matrix | 苏州博进生物技术有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-107754767-B | High-stability immobilized metal chelating affinity chromatography medium | 苏州博进生物技术有限公司 | 2020-04-21 | — | — | CN | claimed |
| CN-107754768-B | Metal chelating affinity chromatography medium containing barrier layer | 苏州博进生物技术有限公司 | 2020-03-31 | — | — | CN | claimed |
| EP-4710920-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF AMLODIPINE, RAMIPRIL AND ROSUVASTATIN | Adamed Pharma S.A. (PL) | 2026-03-18 | — | — | EP | disclosed |
| CN-117282413-A | Nickel ion metal chelating affinity chromatography medium and preparation method thereof | 苏州博进生物技术有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-107754769-B | High-load metal chelating affinity chromatography medium | 苏州博进生物技术有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-107899552-B | Metal chelating affinity chromatography medium using magnetic polymer microsphere as matrix | 苏州博进生物技术有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-107754767-B | High-stability immobilized metal chelating affinity chromatography medium | 苏州博进生物技术有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-107754768-B | Metal chelating affinity chromatography medium containing barrier layer | 苏州博进生物技术有限公司 | 2020-03-31 | — | — | CN | disclosed |
| EP-3454838-B1 | PHARMACEUTICAL COMPOSITION | ADAMED PHARMA S A (PL) | 2020-02-12 | — | — | EP | disclosed |
| EP-3454838-A1 | PHARMACEUTICAL COMPOSITION | Adamed Pharma S.A. (PL) | 2019-03-20 | — | — | EP | disclosed |
| US-9006158-B2 | Polytetrahydrobenzoxazines and bistetrahydrobenzoxazines and use thereof as a fuel additive or lubricant additive | BASF SE (DE) | 2015-04-14 | — | — | US | disclosed |
| EP-2649054-A1 | POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS ADDITIVE TO FUEL OR LUBRICANT | BASF SE (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20130237579-A1 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE HMG-COA REDUCTAS INHIBITIORS | STANLEY TIMOTHY (GB) | 2013-09-12 | — | — | US | disclosed |
| US-20120149617-A1 | POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE | BASF SE (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076428-A1 | POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS ADDITIVE TO FUEL OR LUBRICANT | BASF SE (DE) | 2012-06-14 | — | — | WO | disclosed |
| EP-2178515-A2 | STABLE COMPOSITIONS | Generics Ýuk¨Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010787-A2 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE HMG-COA REDUCTASE INHIBITORS | GENERICS [UK] LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| EP-0181764-A2 | Metallosilicates of Tetravalent Lanthanide and Actinide Series Metals | THE STANDARD OIL COMPANY (US) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149617-A1 | POLYTETRAHYDROBENZOXAZINES AND BISTETRAHYDROBENZOXAZINES AND USE THEREOF AS A FUEL ADDITIVE OR LUBRICANT ADDITIVE | ADH1A, ADH1C, H1-0 | MEN1 4658/4885LMNA 712/4885KMT2A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.